AstraZeneca publishes KALOS, LOGOS trial data

Full results from the Phase III KALOS and LOGOS trials published in The Lancet Respiratory Medicine showed AstraZeneca’s (AZN) Breztri Aerosphere demonstrated statistically significant and clinically meaningful improvements in patients with uncontrolled asthma compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist medicines: Symbicort, PT009 and the Symbicort and PT009 treatment groups combined. Breztri is a single-inhaler, fixed-dose triple-combination of ICS/LABA and a long-acting muscarinic antagonist. In a pre-specified pooled analysis of the primary endpoints across the KALOS and LOGOS trials, Breztri improved lung function by 76mL and 90mL versus dual therapy. In the pooled analysis of KALOS and LOGOS, Breztri also demonstrated clinically meaningful reductions in the annualized rate of severe asthma exacerbations versus ICS/LABA medicines in patients with or without a recent asthma exacerbation. Full results can be found in The Lancet Respiratory Medicine. There were no new safety or tolerability signals identified for Breztri in KALOS or LOGOS.